文献速递临床试验与 GCP

左甲状腺素单药治疗降低老年亚临床甲状腺功能减退症患者心血管疾病风险的疗效与安全性:一项多中心、开放标签、随机对照试验的研究方案

Efficacy and safety of levothyroxine monotherapy in lowering the risk of cardiovascular disease in older adults with subclinical hypothyroidism: research protocols of a multicenter, open-label, randomized controlled trial.
PubMed 文献 · Trials · 2025-05-15

本研究为多中心、开放标签、随机对照试验,计划纳入254例未治疗的老年亚临床甲状腺功能减退症患者,按1:1随机分为左甲状腺素治疗组(每日50微克,体重<50公斤者25微克,维持至少48周使促甲状腺激素正常)和对照组(仅评估甲状腺状态)。主要评估颈动脉内膜中层厚度变化、斑块负荷最大平均变化、血脂谱、骨密度及致命和非致命心血管事件发生率。

要点

  • 纳入254例老年亚临床甲状腺功能减退症患者,随机分为左甲状腺素治疗组和对照组各127例。
  • 治疗组每日左甲状腺素50微克(体重<50公斤者25微克),至少48周,维持促甲状腺激素正常范围。
  • 通过血管超声评估颈动脉内膜中层厚度、斑块负荷、血脂谱、骨密度及心血管事件发生率。

核心结论

  • 本研究将明确左甲状腺素替代治疗能否为老年亚临床甲状腺功能减退症患者带来心血管获益。

研究设计与样本

  • 多中心、开放标签、随机对照试验,计划招募254例符合诊断标准的未治疗老年亚临床甲状腺功能减退症患者,按人群特异性促甲状腺激素参考值诊断。
  • 计划将127例患者随机分入治疗组和对照组,治疗组每日左甲状腺素50微克(体重<50公斤者25微克),至少48周,维持促甲状腺激素在正常范围;对照组仅进行甲状腺状态评估并记录结果。
  • 参与者在试验开始前后完成五次访视,通过血管超声评估颈动脉内膜中层厚度变化、斑块负荷最大平均变化、血脂谱、骨密度及致命和非致命心血管事件发生率。

临床怎么用

  • 原文未据此给出推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This multicenter, open-label, randomized controlled trial (RCT) aims to assess the efficacy and safety of levothyroxine monotherapy in lowering the risk of cardiovascular disease (CVD) in untreated older adults with subclinical hypothyroidism (SCH) who are diagnosed according to population-specific TSH reference values. METHODS: A total of 254 patients with SCH who meet the diagnostic criteria will be recruited, and the baseline clinical data of the patients will be collected. Then, a total of 127 patients will be randomly divided into each of the treatment and control groups, and the treatment group will receive daily levothyroxine doses (Merck Euthyrox® levothyroxine 50 mcg tablet). Specifically, 50 µg of levothyroxine per day will be administered to patients in the treatment group (or 25 µg to patients with a body weight < 50 kg) for at least 48 weeks to maintain thyroid-stimulating hormone (TSH) levels within the normal range. The participants in the control group will be subjected only to thyroid status evaluation, and the results will be recorded. The participants will complete five visits before and after the start of the trial, and differences in the change in carotid intima-media thickness (CIMT), maximum mean change in plaque burden, and changes in lipid profiles, bone mineral densities, and incidences of fatal and nonfatal cardiovascular events between the initial visit and the last follow-up visit will be evaluated via vascular ultrasound. DISCUSSION: We will explicitly address whether levothyroxine replacement therapy provides cardiovascular benefits for older adults with subclinical hypothyroidism. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, No. ChiCTR2400092634. Registered on 30 November 2024. Recruitment for this study began on December 1, 2024, and continues until at least until November 30, 2025.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Xu C, Zhou H, Lu X, et al. Efficacy and safety of levothyroxine monotherapy in lowering the risk of cardiovascular disease in older adults with subclinical hypothyroidism: research protocols of a multicenter, open-label, randomized controlled trial. Trials. 2025. PMID: 40375293. doi:10.1186/s13063-025-08857-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。